Monopar Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Monopar Therapeutics es Chandler Robinson , nombrado en Dec 2014, tiene una permanencia de 9.92 años. compensación anual total es $1.78M, compuesta por 32.6% salario y 67.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.06% de las acciones de la empresa, por valor de $1.13M. La antigüedad media del equipo directivo y de la junta directiva es de 5.7 años y 8.8 años, respectivamente.
Información clave
Chandler Robinson
Chief Executive Officer (CEO)
US$1.8m
Compensación total
| Porcentaje del salario del CEO | 32.6% |
| Permanencia del CEO | 9.9yrs |
| Participación del CEO | 1.1% |
| Permanencia media de la dirección | 5.7yrs |
| Promedio de permanencia en la Junta Directiva | 8.8yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Aug 13
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?
Feb 27Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?
Mar 02We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Nov 16Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive
Oct 05We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate
Jul 30Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
Mar 28We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely
Jul 15Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation
Mar 26Monopar nabs U.S. patent covering camsirubicin
Dec 22Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19
Dec 10Monopar launches validive mid-stage study in chemo-induced oral mucositis
Dec 08Monopar Therapeutics EPS beats by $0.02
Nov 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$6m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$2m | US$580k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$2m | US$550k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$10m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | US$1m | US$525k | -US$9m |
| Sep 30 2021 | n/a | n/a | -US$9m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$7m |
| Dec 31 2020 | US$2m | US$504k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$5m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | US$541k | US$386k | -US$4m |
| Sep 30 2019 | n/a | n/a | -US$4m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$1m | US$375k | -US$3m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Jun 30 2018 | n/a | n/a | -US$17m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | US$401k | US$331k | -US$17m |
Compensación vs. Mercado: La compensación total de Chandler($USD1.78M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.07K).
Compensación vs. Ingresos: La compensación de Chandler ha aumentado mientras la empresa no es rentable.
CEO
Chandler Robinson (40 yo)
9.9yrs
Permanencia
US$1,778,655
Compensación
Dr. Chandler D. Robinson, M.D., MBA, MSc, Co-Founded Monopar Therapeutics Inc. in 2010 and has been Chief Executive Officer and Director since December 2014 and serves as President. Among his previous expe...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Independent Executive Chairman of the Board | 9.9yrs | US$264.04k | 0.29% $ 302.6k | |
| Co-Founder | 9.9yrs | US$1.78m | 1.06% $ 1.1m | |
| Chief Operating Officer | 3.4yrs | US$911.14k | 0.76% $ 801.4k | |
| CFO, Principal Accounting Officer & Principal Financial Officer | less than a year | sin datos | 0.029% $ 31.2k | |
| Acting Chief Medical Officer | 7.9yrs | sin datos | sin datos |
5.7yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MNPR es experimentado (5.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Independent Executive Chairman of the Board | 9.9yrs | US$264.04k | 0.29% $ 302.6k | |
| Co-Founder | 9.9yrs | US$1.78m | 1.06% $ 1.1m | |
| Independent Director | 9.9yrs | US$126.04k | 0.89% $ 948.2k | |
| Independent Director | 7.6yrs | US$136.54k | 0.10% $ 108.0k | |
| Independent Director | 7.3yrs | US$128.54k | 0.12% $ 124.1k | |
| Director | 1.7yrs | US$848.44k | 0.22% $ 230.9k |
8.8yrs
Permanencia media
65.5yo
Promedio de edad
Junta con experiencia: La junta directiva de MNPR se considera experimentada (8.8 años de antigüedad promedio).